Hologic, Inc. (NASDAQ:HOLX) Shares Purchased by Quantinno Capital Management LP

Quantinno Capital Management LP boosted its stake in shares of Hologic, Inc. (NASDAQ:HOLX) by 46.1% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 60,541 shares of the medical equipment provider’s stock after acquiring an additional 19,117 shares during the quarter. Quantinno Capital Management LP’s holdings in Hologic were worth $4,364,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds and other institutional investors also recently modified their holdings of the company. Barclays PLC lifted its holdings in shares of Hologic by 47.6% during the third quarter. Barclays PLC now owns 718,231 shares of the medical equipment provider’s stock worth $58,507,000 after purchasing an additional 231,578 shares during the period. Avanza Fonder AB acquired a new stake in shares of Hologic in the 4th quarter worth $1,861,000. Brooklyn Investment Group lifted its stake in shares of Hologic by 14.7% in the 4th quarter. Brooklyn Investment Group now owns 1,131 shares of the medical equipment provider’s stock worth $82,000 after acquiring an additional 145 shares during the period. UMB Bank n.a. boosted its holdings in shares of Hologic by 4.1% in the fourth quarter. UMB Bank n.a. now owns 4,758 shares of the medical equipment provider’s stock valued at $343,000 after acquiring an additional 188 shares in the last quarter. Finally, LaFleur & Godfrey LLC increased its stake in shares of Hologic by 2.9% during the fourth quarter. LaFleur & Godfrey LLC now owns 130,373 shares of the medical equipment provider’s stock worth $9,399,000 after acquiring an additional 3,655 shares during the period. 94.73% of the stock is currently owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In other Hologic news, Director Martin D. Madaus bought 5,445 shares of Hologic stock in a transaction that occurred on Wednesday, May 7th. The shares were purchased at an average cost of $55.24 per share, for a total transaction of $300,781.80. Following the completion of the transaction, the director now owns 5,445 shares of the company’s stock, valued at $300,781.80. This represents a ∞ increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. 1.88% of the stock is owned by corporate insiders.

Hologic Price Performance

Shares of NASDAQ HOLX opened at $56.79 on Monday. The stock has a market cap of $12.66 billion, a price-to-earnings ratio of 17.91, a PEG ratio of 2.14 and a beta of 0.54. Hologic, Inc. has a 52 week low of $51.90 and a 52 week high of $84.67. The company’s 50-day moving average price is $58.76 and its 200 day moving average price is $67.32. The company has a current ratio of 3.49, a quick ratio of 2.78 and a debt-to-equity ratio of 0.52.

Hologic (NASDAQ:HOLX) last issued its quarterly earnings data on Thursday, May 1st. The medical equipment provider reported $1.03 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.02 by $0.01. Hologic had a return on equity of 19.72% and a net margin of 18.42%. The business had revenue of $1.01 billion for the quarter, compared to the consensus estimate of $1 billion. During the same period in the prior year, the business earned $1.03 earnings per share. The business’s revenue was down 1.2% on a year-over-year basis. As a group, research analysts forecast that Hologic, Inc. will post 4.28 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of equities research analysts recently commented on HOLX shares. Raymond James restated an “outperform” rating and issued a $71.00 price objective (down previously from $90.00) on shares of Hologic in a research report on Friday, May 2nd. Leerink Partners cut Hologic from an “outperform” rating to a “market perform” rating and reduced their price target for the company from $80.00 to $75.00 in a report on Thursday, February 6th. William Blair reaffirmed an “outperform” rating on shares of Hologic in a report on Thursday, February 6th. Leerink Partnrs cut Hologic from a “strong-buy” rating to a “hold” rating in a research report on Thursday, February 6th. Finally, Morgan Stanley decreased their target price on shares of Hologic from $77.00 to $65.00 and set an “equal weight” rating on the stock in a research report on Monday, May 5th. Twelve analysts have rated the stock with a hold rating, five have assigned a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, Hologic has a consensus rating of “Hold” and a consensus price target of $77.42.

Hologic Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.